Roche loses appeal to block market entry of rival cancer drug
07-07-2020
Hatch-Waxman amendment: a Hobson’s choice
08-08-2018
Senator proposes Hatch-Waxman change to boost generic development
15-06-2018
berezko / iStockphoto.com
The inter partes review (IPR) process has had a huge impact on biosimilar litigation, but it isn’t truly fulfilling its goal of being an alternative to district court litigation.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AIPPI 2018, Eli Lilly, IPR, inter partes review, biosimilar, UCB, Manisha Desai, Mark Stewart
